The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1662
October 31, 2022
View Complete Issue         Table of Contents 2019 
Two New Oral Testosterone Products for Hypogonadism
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two New Oral Testosterone Products for Hypogonadism
October 31, 2022 (Issue: 1662)
The FDA has approved two new oral formulations of testosterone undecanoate — Kyzatrex (Marius) and Tlando (Antares) — for treatment of males with a deficiency of endogenous testosterone due to conditions such as Klinefelter...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Two New Oral Testosterone Products for Hypogonadism
Article code: 1662b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.